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Ιθάκη                                                                                          
Σα βγεις στον πηγαιμό για την Ιθάκη, να 
εύχεσαι νάναι μακρύς ο δρόμος, γεμάτος 
περιπέτειες, γεμάτος γνώσεις. Τους 
Λαιστρυγόνας και τους Κύκλωπας, τον 
θυμωμένο Ποσειδώνα μη φοβάσαι, τέτοια 
στον δρόμο σου ποτέ σου δεν θα βρείς, 
αν μέν' η σκέψις σου υψηλή, αν εκλεκτή 
συγκίνησις το πνεύμα και το σώμα σου 
αγγίζει. Τους Λαιστρυγόνας και τους 
Κύκλωπας, τον άγριο Ποσειδώνα δεν θα 
συναντήσεις, αν δεν τους κουβανείς μες 
στην ψυχή σου, αν η ψυχή σου δεν τους 
στήνει εμπρός σου. 
Να εύχεσαι νάναι μακρύς ο δρόμος. 
Πολλά τα καλοκαιρινά πρωϊά να είναι 
που με τι ευχαρίστησι, με τι χαρά θα 
μπαίνεις σε λιμένας πρωτοειδωμένους· να 
σταματήσεις σ' εμπορεία Φοινικικά, και τες 
καλές πραγμάτειες ν' αποκτήσεις,
σεντέφια και κοράλλια, κεχριμπάρια κ' 
έβενους, και ηδονικά μυρωδικά κάθε 
λογής, όσο μπορείς πιο άφθονα ηδονικά 
μυρωδικά· σε πόλεις Αιγυπτιακές πολλές 
να πας, να μάθεις και να μάθεις απ' τους 
σπουδασμένους.
Πάντα στον νου σου νάχεις την Ιθάκη. Το 
φθάσιμον εκεί είν' ο προορισμός σου. Αλλά 
μη βιάζεις το ταξίδι διόλου. Καλλίτερα 
χρόνια πολλά να διαρκέσει· και γέρος 
πια ν' αράξεις στο νησί, πλούσιος με όσα 
κέρδισες στον δρόμο, μη προσδοκώντας 
πλούτη να σε δώσει η Ιθάκη.
Η Ιθάκη σ' έδωσε το ωραίο ταξίδι. Χωρίς 
αυτήν δεν θάβγαινες στον δρόμο. Αλλο δεν 
έχει να σε δώσει πια. 
Κι αν πτωχική την βρεις, η Ιθάκη δεν 
σε γέλασε. Ετσι σοφός που έγινες, με τόση 
πείρα, ήδη θα το κατάλαβες η Ιθάκες τι 
σημαίνουν. 
Κωνστάντινος Π. Καβαφης, 1911
Ithaca 
When you set out on your journey to Ithaca, 
pray that the road is long, full of adventure, 
full of knowledge. The Lestrygonians and 
the Cyclops, the angry Poseidon - do not 
fear them: You will never fi nd such as these 
on your path, if your thoughts remain lofty, 
if a fi ne emotion touches your spirit and 
your body. The Lestrygonians and the Cy-
clops, the fi erce Poseidon you will never 
encounter, if you do not carry them within 
your soul, if your soul does not set them up 
before you.
Pray that the road is long. That the sum-
mer mornings are many, when, with such 
pleasure, with such joy you will enter ports 
seen for the fi rst time; stop at Phoenician 
markets, and purchase fi ne merchandise, 
mother-of-pearl and coral, amber and eb-
ony, and sensual perfumes of all kinds, as 
many sensual perfumes as you can; visit 
many Egyptian cities, to learn and learn 
from scholars.
Always keep Ithaca in your mind. To ar-
rive there is your ultimate goal. But do not 
hurry the voyage at all. It is better to let it 
last for many years; and to anchor at the 
island when you are old, rich with all you 
have gained on the way, not expecting that 
Ithaca will offer you riches. 
Ithaca has given you the beautiful voy-
age. Without her you would have never set 
out on the road. She has nothing more to 
give you. 
And if you fi nd her poor, Ithaca has not 
deceived you. Wise as you have become, 
with so much experience, you must already 
have understood what Ithacas mean.
Konstantinos P. Kavafi s, 1911 
                               To Evi, the love of my life 
and, to Melina and Ioanna, the meaning of it

ABSTRACT
Background: Heart failure (HF) is a major public health problem affecting at least 26 million 
people worldwide and one of the leading causes of disability and death.
Aims: To identify characteristics associated with improved or worsened prognosis in patients 
with established HF and to study factors associated with higher risk for the incidence of HF in 
the general population.
Methods and Results: This thesis consists of four papers. Paper I was designed to study the 
impact of different dose levels of beta-blockers (BBs) and angiotensin-converting enzyme 
inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) on long-term mortality in elderly 
patients with HF with reduced ejection fraction (EF). The study cohort included 184 HF pa-
tients aged ≥80 years with EF ≤40%. The target ACEI/ARB dose was associated with reduced 
all-cause mortality compared to <50% of target dose. There were no signifi cant differences 
in survival between the different BB doses. In Paper II, a comparison of the prevalence and 
prognostic contribution to mortality of non-cardiac comorbidities was conducted between HF 
patients with EF <50% and ≥50%. Data from the Swedish Heart Failure Registry between 
May 2000 and December 2012 were used. Stroke, anemia, gout, and cancer were all associ-
ated with higher mortality in both phenotypes with similar impact, whereas diabetes, renal 
failure, and liver disease had a higher impact in patients with EF <50%. Pulmonary disease 
was more prominent in patients with EF ≥50%. In Paper III, the predictive value of different 
biomarkers for HF incidence was examined. The study cohort was a randomly selected sample 
of men born in 1943 who were followed up over 21 years. N-terminal pro B-type natriuretic 
peptide (NT-proBNP) ≥25ng/L and high-sensitivity C-reactive protein (hs-CRP) >3mg/L at 
age 50 years were associated with higher odds of incident HF. Paper IV studied and compared 
risk factors and incidence of HF in middle-aged men born 30 years apart. The study popula-
tion consisted of a sample of men born in 1943 (described in Paper III) and a similar sample 
of men born in 1913. The impact of different factors on the risk of developing HF was exam-
ined. Eighty men born in 1913 (9.4%) and 42 men born in 1943 (5.3%) developed HF during 
follow-up with an adjusted hazard ratio comparing the two cohorts of 0.46 (95% confi dence 
interval 0.28–0.74, p=0.002). In both cohorts, higher body mass index, higher diastolic blood 
pressure, treatment for hypertension, and onset of atrial fi brillation, ischemic heart disease, or 
diabetes mellitus were associated with higher risk of HF. Higher heart rate was associated with 
an increased risk only in men born in 1913, whereas higher systolic blood pressure, smoking, 
higher glucose, higher cholesterol, and physical inactivity were associated with an increased 
HF risk in men born in 1943. The relative importance of atrial fi brillation as a risk factor de-
creased, whereas that of systolic blood pressure and physical inactivity increased in men born 
in 1943 compared with men born in 1913. 
Conclusions: Titration to the target ACEI/ARB dose is benefi cial with respect to mortality in 
elderly patients with HF. Non-cardiac comorbidities contribute signifi cantly to mortality in 
both HF phenotypes with some notable differences. NT-proBNP and hs-CRP have a predictive 
value for the incidence of HF in middle-aged men. The incidence of HF in middle-aged 
men has decreased during the past 30 years and, in the meantime, the risk profi le for HF has 
also changed.
Keywords: Heart failure, prognosis, characteristics, risk factors, incidence, prediction
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SVENSK SAMMANFATTNING
Bakgrund: Hjärtsvikt (HF) är ett stort folkhälsoproblem som drabbar minst 26 miljoner 
människor världen över och är en ledande orsak till funktionsnedsättning och mortalitet.
Syfte: Att identifi era tillstånd som är förknippade med förbättrad eller förvärrad prognos 
hos patienter med etablerad HF och att studera faktorer som är associerade med högre 
risk för incidens av HF i den allmänna populationen.
Metoder och Resultat: Avhandlingen består av fyra delarbete. Arbete I var utformat 
för att studera effekten av olika dosnivåer av beta-blockerare (BB) och angiotensin 
konverterings enzym hämmare (ACEIs) på mortalitet hos äldre patienter med HF med 
reducerad ejektionsfraktion (EF). Studiekohorten var 184 HF patienter i åldern ≥80 
med HF och EF ≤40%. Måldosen ACEis var associerad med lägre mortalitet jämfört 
med <50% av måldosen. Inga signifi kanta skillnader i överlevnad hittades mellan BBs-
dosgrupperna. I Arbete II genomfördes en jämförelse för prevalensen och för den prog-
nostiska betydelsen av icke-kardiella komorbiditeter på mortalitet mellan patienter med 
HF med EF <50% och HF med EF ≥50%. Data från det svenska hjärtsviktregistret 
mellan maj 2000 och december 2012 analyserades. Stroke, anemi, gikt och cancer var 
alla förknippade med högre mortalitet i båda fenotyperna med liknande effekt, medan 
diabetes, njursvikt och leversjukdom hade en högre påverkan på mortalitet hos patien-
ter med EF <50%. Lungsjukdom var mer framträdande hos patienter med EF ≥50%. 
I arbete III undersöktes det prediktiva värdet av olika biomarkörer för uppkomst av 
HF hos 50-åriga män. Studiekohorten var ett slumpmässigt urval av män födda 1943 
som följdes upp under 21 år. N-terminal pro b-type natriuretic peptide (NT-proBNP) 
≥25ng/L och high-sensitivity C-reactive protein (hs-CRP) >3mg/L vid 50 års ålder var 
associerat med högre odds för insjuknande i HF. Arbete IV studerade och jämförde 
riskfaktorer och incidensen av HF hos 2 kohorter av medelålders män födda 30 år från 
varandra. Kohorten av män födda 1943 (beskrivet i Arbete III) och ett liknande urval av 
män födda 1913 utgjorde den studiepopulationen. Effekterna av olika faktorer på risken 
för att utveckla HF undersöktes. Åttio män födda 1913 (9.4%) och 42 män födda 1943 
(5.3%) utvecklade hjärtsvikt under uppföljningstiden, justerad hazard ratio (födda 1943 
vs 1913): 0.46 (95% konfi densintervall 0.28–0.74, p=0.002). I båda kohorterna var  högre 
kroppsmasseindex, högre diastoliskt blodtryck, behandling för högt blodtryck, förekomst 
av förmaksfl immer, ischemisk hjärtsjukdom och diabetes mellitus associerade med högre 
risk för HF. Högre hjärtfrekvens var förknippad med en ökad risk endast hos män födda 
1913 medan högre systoliskt blodtryck, rökning, högre glukos, högre kolesterol och 
fysisk inaktivitet var förknippade med högre risk hos män födda 1943. Den relativa be-
tydelsen av förmaksfl immer som riskfaktor har minskat medan betydelsen av systoliskt 
blodtryck och fysisk inaktivitet har ökat i kohort 1943 jämfört med 1913.
Slutsatser: Upptitrering till måldos av ACEI är fördelaktig för överlevnad hos äldre 
patienter med HF och EF <40%. Icke kardiella komorbiditeter har ett signifi kant bidrag 
till dödligheten i båda HF-fenotyperna med några skillnader. NT-proBNP och hs-CRP 
har ett prediktivt värde för uppkomst av HF hos medelålders män. Incidensen av hjärt-
svikt hos medelålders män har minskat de senaste 30 åren och under tiden har riskpro-
fi len för hjärtsvikt också förändrats.
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9ABBREVIATIONS
ACEI   Angiotensin-converting enzyme inhibitor
ARB   Angiotensin II receptor blocker
BB   Beta-blocker
BP   Blood pressure
BMI   Body mass index 
CI   Confi dence interval
DBP   Diastolic blood pressure
EF   Ejection fraction
HF   Heart failure
HFmrEF  Heart failure with mid-range ejection fraction
HFpEF   Heart failure with preserved ejection fraction
HFrEF   Heart failure with reduced ejection fraction
HR   Hazard ratio
hs-CRP   High-sensitivity C-reactive protein
IL-6   Interleukin-6
MRA   Mineralocorticoid receptor antagonist
NT-proBNP  N-terminal prohormone of B-type natriuretic peptide
OR   Odds ratio
ROC   Receiver operating characteristic 
SBP   Systolic blood pressure
SD   Standard deviation
SwedeHF  Swedish Heart Failure Registry
TIA   Transient ischemic attack
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INTRODUCTION
 “The very essence of cardiovascular practice is the early detection of heart failure”
Sir Thomas Lewis, 1933
Defi nition of heart failure
Heart failure (HF) is a complex clinical syndrome, for which several defi nitions have 
been proposed. The European Society of Cardiology defi nes HF as a clinical syn-
drome characterized by symptoms such as shortness of breath, persistent coughing 
or wheezing, ankle swelling, and fatigue that may be accompanied by the following 
signs: jugular venous pressure, pulmonary rales, increased heart rate, and peripheral 
edema (Table 1).1 
According to Braunwald’s Heart Disease,2 HF is defi ned as the pathological state 
in which an abnormality of cardiac function is responsible for failure of the heart to 
pump blood at a rate commensurate with the requirements of the metabolizing tissues, 
or to do so only from an elevated fi lling pressure.
? Shortness of breath 
(dyspnea)?
? Fatigue? ? Weakness?
? Swelling (edema) in legs 
and ankles?
? Rapid heartbeat? ? Persistent cough or 
wheezing?
? Increased need to urinate 
at night (nocturia)?
? Reduced ability to 
exercise?
? Dyspnea when lying 
down (orthopnea)?
Table 1. Symptoms of heart failure
History of heart failure
Descriptions of HF exist from ancient Egypt, Greece, and India. An Egyptian digni-
tary who died 3,500 years and was discovered in 1904 in the Egyptian city of Luxor 
(the mummy of Nebiri) may be the oldest known victim of HF. Histology of the lungs 
showed the presence of pulmonary edema, which was likely due to HF, as histochemi-
cal staining of lung tissue ruled out other diseases as a cause of ‘fl uid in the air spaces 
of the lung’, including tuberculosis, granulomas, or bacterial infections.3 
A description of rales is found in the Hippocratic corpus: “When the ear is held to the 
chest, and one listens for some time, it may be heard to see the inside like the boiling 
of vinegar”. It also discussed a way to drain this fl uid through a hole drilled in a rib.4
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1628 William Harvey described the circulation 
1785 William Withering published an account of the medical use of digitalis 
1895 Willem Einthoven invented the first practical electrocardiogram 
1895 Wilhelm Conrad Roentgen discovered X-rays 
1918 Ernest Henry Starling published the Frank-Starling law of the heart 
1954 Inge Edler and Hellmuth Hertz used ultrasound to image cardiac structures 
1967 Christiaan Barnard performed the first human heart transplant 
1987 CONSENSUS-I Study showed survival benefit of ACEIs in heart failure 
1995 European Society of Cardiology published the first guidelines for heart failure 
Table 2. History of major milestones in heart failure
Important elements in the history of HF over the centuries that followed are presented 
in the Table 2.5
Classifi cation of heart failure related to ejection fraction
Left ventricular ejection fraction (EF) is used for the classifi cation of HF into differ-
ent categories. EF defi nes as the fraction of chamber volume ejected in systole (stroke 
volume) in relation to the volume of the blood in the ventricle at the end of diastole 
(end-diastolic volume). The American Society of Echocardiography and the European 
Association of Cardiovascular Imaging consider a normal EF and normal range as 
62% (52–72%) in men and 64% (54–74%) in women.6
HF with preserved EF (HFpEF) is characterized by EF ≥50% and additional obliga-
tory criteria including diastolic abnormalities on echocardiography7 in both European 
and American guidelines.1, 8 EF <50% is considered reduced and this type of HF was 
until recently defi ned as HF with reduced EF (HFrEF). However, the defi nition of 
patients with EF in the range of 40–49% has been considered a ‘grey area’, which was 
defi ned as HF with mid-range EF (HFmrEF) in the latest update of European Society 
of Cardiology guidelines (Table 3).1 
Epidemiology of heart failure
HF is a major public health problem affecting more than 26 million people world-
wide.9, 10 According to data from the Framingham Heart Study, the lifetime risk for 
developing HF at 40 years of age is approximately 20% for both men and women.11 
In Sweden, the prevalence of HF is estimated to be about 2% and increases with age, 
rising to ≥10% in those over 70 years.12, 13 Data from 2.1 million Swedish inhabitants 
show that the mean age at fi rst diagnosis of HF was 77 years12 and the incidence was 
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Criteria Type of heart failure 
 HFrEF HFmrEF HFpEF 
1 Symptoms/signs Symptoms/signs Symptoms/signs 
2 EF <40% EF 40–49% EF ?50% 
3 – 1. Elevated levels of natriuretic 
    peptide 
1. Elevated levels of natriuretic 
    peptide 
  2. At least one additional criterion 2. At least one additional criterion 
   a. Relevant heart structure heart 
     disease (LVH and/or LAE) 
 a. Relevant heart structure heart 
        disease (LVH and/or LAE) 
   b. Diastolic dysfunction     b. Diastolic dysfunction 
EF, ejection fraction; HFmrEF, heart failure with mid-range EF; HFpEF, heart failure with preserved EF; HFrEF, heart 
failure with reduced ejection fraction; LAE, left atrial enlargement; LVH, left ventricular hypertrophy. 
Table 3. Defi nition of heart failure according to 2016 European Society of Cardiology guidelines
3.8/1000 person-years. The epidemiology of HF is evolving. Data suggests that the 
incidence of HF peaked in the mid-1990s and has since declined, except in younger 
individuals where the incidence has increased.14-16 Increased life expectancy and im-
proved HF management have led to an increased HF prevalence. It is estimated that 
the prevalence of HF will increase by 46% from 2012 to 2030.17
The proportion of patients with HFrEF compared to those with HFpEF varies signifi -
cantly between studies. Approximately half of patients with HF have preserved EF, 
although the percentage of HFpEF ranges signifi cantly depending on the defi nition 
applied and the population studied.18-23
Guideline-directed medical therapy of heart failure
Neurohormonal blockers such as angiotensin-converting enzyme inhibitors (ACEIs), 
angiotensin II receptor blockers (ARBs), beta-blockers (BBs), and mineralocorticoid 
receptor antagonists (MRAs) have been proven to decrease morbidity and mortality 
in HFrEF and are therefore recommended by guidelines as the cornerstone in therapy 
for HFrEF patients.24-31
In patients who remain symptomatic despite optimal treatment with ACEI/ARB, BB, 
and MRA, sacubitril/valsartan is recommended as a replacement for an ACEI/ARB to 
further reduce the risk of hospitalization and death as well as to improve symptomatic 
relief and quality of life.32 In the case of a resting heart rate ≥70/min in sinus rhythm 
despite optimal treatment including BB, ivabradine should be considered.33
In addition to pharmacologic therapy, cardiac resynchronization therapy and im-
plantable cardioverter defi brillator therapy are key components in the management 
of HFrEF. Implantable cardioverter defi brillators are recommended for secondary 
prevention in patients with a history of ventricular tachycardia as well as primary 
prevention in symptomatic patients with EF ≤35% despite optimal medical treatment. 
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Cardiac resynchronization therapy has been shown to reduce morbidity and mortality 
in selected patients with HF34 and should be considered in symptomatic patients with 
EF ≤35% despite optimal medical treatment when QRS duration is ≥130 msec.
On the contrary, no treatment has yet been shown, convincingly, to reduce mortality 
in patients with HFpEF or HFmrEF (patients with HFmrEF have generally been in-
cluded in trials of patients with HFpEF).35-41 All outcome trials in HFpEF to date have 
failed to demonstrate survival benefi t, despite robust evidence of prognostic benefi t 
using the same agents in HFrEF. However, it is worth mentioning that recent post-hoc 
analyses have suggested benefi ts from medical treatment may be present in patients 
with HFmrEF.39, 42,43
Challenges of applying guideline-directed medical therapy in clinical 
practice
The fi rst step in the therapeutic algorithm recommended by guidelines for patients 
with symptomatic HFrEF is the initiation of an ACEI (or an ARB if the patient is 
ACEI intolerant) and a BB at low doses with subsequent titration to maximum tol-
erated evidence-based doses.1 However, observational studies in the real-world set-
ting demonstrate that only around one-third of HF patients receive the target dose of 
either ACEI/ARB and/or BB.44, 45 Likewise, in the Swedish Heart Failure Registry 
(SwedeHF) only two-thirds reached ≥50% of the target dose for either ACEI or BB.46 
Furthermore, there is a limited number of studies examining the association between 
medication dose and outcome in HF patients. These studies suggest an outcome ben-
efi t by using higher compared to lower doses of ACEIs, ARBs, or BBs.47-50
To date, most clinical trials have been conducted primarily in relatively young patients 
with HF. However, compared with participants in studies, HF patients in daily clinical 
practice are often older with several comorbidities and have a low tolerability for dif-
ferent medical treatments. Is guideline-directed medical therapy equally benefi cial in 
elderly compared to younger HF patients? Evidence regarding the optimal dose in this 
group of patients is limited. The question raised is whether the dose-related benefi t for 
prognosis suggested by the available studies in HFrEF patients also applies for elderly 
patients in the real-world setting.
Comorbidities in heart failure
Comorbidity refers to chronic conditions that coexist with the condition being de-
scribed. A commonly used classifi cation is cardiac (ischemic heart disease, atrial fi -
brillation, etc.) and non-cardiac diseases. Both types of comorbidities accompany HF 
with higher frequency in these patients compared to age-matched controls.51 Non-
cardiac comorbidities are highly prevalent: 75% of HF patients have at least one co-
morbidity51 and about 40% of them have ≥5, with renal disease, anemia, and diabetes 
mellitus being the most common.52
There is a growing recognition that the burden of comorbidities increases the risk of 
mortality and decreases quality of life,53-55 suggesting that targeting comorbidities as a 
part of HF care may be benefi cial for prognosis.56
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Compared to patients with HFrEF, those with HFpEF are more frequently women, 
older, have a higher prevalence of obesity and atrial fi brillation, and have a lower 
incidence of ischemic heart disease.57-60 Previous studies suggest a higher prevalence 
of non-cardiac illnesses among HFpEF compared to HFrEF patients,61-63 leading to 
the belief that comorbidities might play a more signifi cant role in HFpEF.64 However, 
recent studies demonstrate similar prevalence between these two HF phenotypes.51, 65 
Few studies have compared the relative impact of non-cardiac comorbidities on prog-
nosis in patients with HFrEF compared to HFpEF and available results have been 
inconsistent.61, 66-70
Prognosis in heart failure 
The improved management of HF has reduced mortality rates by as much as 50% over 
the past decades, although both short- and long-term mortality rates remain high.71, 72 
In fact, men and women with a diagnosis of HF seem to have worse survival than pa-
tients with one of several common cancers.73 The 1-year mortality rate for HF patients 
in Sweden in 2016 was 16.8% according to the SwedeHF annual report.46 Approxi-
mately 50% of patients diagnosed with HF die within 5 years.73, 74
The survival of HF patients is infl uenced by several factors including age, sex, the 
cause of HF, and hospitalizations. The mortality rate in treated patients with HF in-
creases with advancing age in both sexes.75 Prognosis has generally been better in 
women than men. In the Framingham Study, the median survival time after diagnosis 
was 3.2 years in women and 1.7 years in men.75 The etiology of HF may be predictive 
of long-term outcome. Peripartum cardiomyopathy has better prognosis compared to 
patients with ischemic heart disease or infi ltrative myocardial disease, such as amy-
loidosis.76 Furthermore, the need for hospitalization is an important marker of poor 
prognosis.77
Does prognosis differ between HFrEF and HFpEF? To date, mortality rates reported 
in studies for HFrEF compared to HFpEF are strongly infl uenced by the study popula-
tion, the inclusion criteria applied, and the defi nitions used for the two HF phenotypes. 
A meta-analysis of randomized trials found a higher mortality rate in HFrEF,78 while 
epidemiological studies demonstrated similar mortality rates.79-81 However, a study 
that included all patients hospitalized at Sahlgrenska University Hospital/Östra for 
HF between May 2007 and April 2008 showed that patients with HFpEF have a better 
long-term prognosis.82 The majority of deaths in both categories are cardiovascular 
deaths. However the proportion of deaths that are cardiovascular related is higher in 
HFrEF than in HFpEF.83-85
Risk-factors for the development of heart failure
The major efforts in HF research to date have focused on treatment, outcomes, and 
prognosis as well as the structured management of patients with the clinical syndrome 
of HF. In order to highlight the importance of HF prevention, the American Heart As-
sociation and American College of Cardiology have proposed a classifi cation scheme 
for HF to include “Stage-A” patients, i.e., those who do not have structural heart dis-
ease but are at risk for developing HF.8
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A variety of factors are known to be associated with higher risk of developing HF, 
ranging from lifestyle characteristics (smoking, physical inactivity) to common medi-
cal conditions (hypertension, ischemic heart disease, atrial fi brillation, diabetes mel-
litus, obesity).86-90 Ways to reduce the risk of HF are summarized in Table 4.
Lifestyle factors Medical conditions 
? Physical activity? ? Treat high blood pressure?
? Healthy weight? ? Treat atrial fibrillation?
? No smoking  ? Control diabetes 
? Healthy eating? ? Maintain healthy cholesterol levels?
Table 4. Ways to reduce the risk of heart failure
The Framingham Heart Study is a landmark achievement that has provided signifi cant 
evidence about the incidence and the risk profi le of HF in the general population. 
Investigations have found that hypertension and coronary heart disease are the two 
most common conditions preceding the onset of HF and, in addition, diabetes mellitus 
and electrocardiographic left ventricular hypertrophy are also associated with higher 
risk of developing HF.91 A recognized limitation in Framingham Heart Study is that 
emerging risk factors were not incorporated, such as bodyweight and physical inactiv-
ity, as well as the lack of randomization of the study cohort.
Changes in lifestyle, new medications, and advances in medical technology during the 
past half century have likely affected the prevalence of cardiovascular risk factors as 
well as modifying the prognosis of the majority of cardiovascular diseases. Popula-
tion-based observational studies have examined the secular trends of cardiovascular 
risk factors and have reported signifi cant changes.92-95 During this time period, serum 
total cholesterol levels, systolic and diastolic blood pressure, and smoking have de-
creased, while the prevalence of obesity has escalated.95, 96 Meanwhile, the prognosis 
of several cardiovascular diseases, with ischemic heart disease probably being the 
most applicable example, has been greatly improved. The mortality rate from isch-
emic heart disease has decreased dramatically in the past four decades in developed 
countries.97, 98 A similar trend in ischemic heart disease was observed in two cohorts of 
middle-aged men living in Gothenburg born 30 years apart.99 
It is, however, worth mentioning that secondary prevention after myocardial infarc-
tion remains suboptimal. In a study from our group only 3.5% of patients achieved six 
pre-specifi ed prevention goals 2 years after acute myocardial infarction and non-fatal 
cardiovascular events occurred in 46.5% of the participants.100 A reasonable ques-
tion is whether the above-described changes in cardiovascular risk factors and dis-
eases have an impact on the incidence and risk profi le of HF in the contemporary era 
with gradually improved primary and secondary cardiovascular prevention (despite 
remaining suboptimal).
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Biomarkers as predictors of incident heart failure
An increasing number of enzymes, hormones, peptides, and proteins, which are re-
ferred to as biomarkers, appear to be associated with HF. Measuring their concentra-
tions in the circulation can be a convenient and non-invasive approach to provide 
important information about disease severity and helps in the detection, diagnosis, 
prognosis, and management of the disease.101 These biomarkers may refl ect differ-
ent mechanisms that seem to coexist in the complex pathophysiology of HF such as 
myocyte stress, infl ammation, myocyte injury, oxidative stress, and sustained neuro-
hormonal overactivation.102
Natriuretic peptides, as indicators of hemodynamic stress, have an essential role in HF 
diagnosis as well as the evaluation of HF treatment.103-107 N-terminal prohormone of 
B-type natriuretic peptide (NT-proBNP) is probably the most widely used biomarker 
and is included in the diagnostic algorithm suggested in the most recent European 
guidelines.1 Even infl ammation seems to be important in the pathogenesis and pro-
gression of HF.108 Available data suggest that elevated circulating infl ammatory cy-
tokines and high-sensitivity C-reactive protein (hs-CRP) are associated with worse 
prognosis in patients with established HF.109-114 Another protein associated with worse 
prognosis in HF is cystatin C, a well-known biomarker of renal function which also 
indicates the level of oxidative stress in the human body.115
Compared to prognostic studies of biomarkers in HF, studies regarding the predictive 
value of biomarkers for incident HF in the general population are scarce.68, 116 How 
useful are biomarkers as predictors of incident HF? There have been some studies 
about the identifi cation of risk factors for HF and risk assessment scores have been 
developed.89, 117 However, these scores were based on specifi c subgroups (e.g., elderly, 
patients with hypertension), so they cannot be applied in a general population, and 
furthermore, the majority of them have not been externally validated. In addition, it 
is known that HF can occur in individuals in the absence of any known risk factors. 
Furthermore, asymptomatic left ventricular dysfunction frequently antecedes HF but 
routine echocardiography is very expensive for use as a screening method. Since dif-
ferent biomarkers represent different pathophysiological mechanisms involved in HF, 
it is assumed that a panel of such biomarkers may facilitate the identifi cation of indi-
viduals at risk for HF at an early stage. The role of a single biomarker as a predictor of 
HF incidence has been examined. In the Framingham Study, interleukin-6 (IL-6) was 
associated with a higher risk of HF in patients without prior myocardial infarction.116 
However, studies using a panel of biomarkers refl ecting different pathophysiological 
mechanisms in a general population for incident HF are sparse.
“Prevention is better than cure”
Desiderius Erasmus
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AIMS
General aims
The general aims of this thesis are: 1) to study the association between different char-
acteristics and prognosis in patients with established HF; and 2) to study character-
istics associated with higher risk for the incidence of HF in the general population.
Specifi c aims
   •  To examine whether elderly patients with HF and EF ≤40% treated with 
≥50% of ACEI/ARB and/or BB target dose have better prognosis in terms of 
mortality compared to those receiving <50% of target dose, despite maximum 
titration. In addition, to study whether the target dose outperforms all other 
doses (Paper I).
   •   To compare the prevalence and prognostic contributions of non-cardiac co-
morbidities to all-cause mortality in patients with EF <50% and ≥50%. In ad-
dition, to examine whether an increasing number of non-cardiac comorbidi-
ties is associated with a higher risk of mortality and if this risk is similar in 
the two HF phenotypes. Finally, to examine possible variations in the impact 
of each comorbidity on mortality over a 12-year study period (Paper II).
   •   To evaluate whether biomarkers proven to be useful prognostic predictors in 
patients with established HF could predict the onset of HF in middle-aged 
men from the general population during a 21-year follow-up (Paper III).
   •   To compare the incidence and risk factors of HF in middle-aged men from the 
general population born 30 years apart, in 1913 and 1943, respectively (Paper 
IV).
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SUBJECTS AND METHODS
Paper I
Study population
This was a retrospective study of 184 consecutive HF patients aged ≥80 years and 
EF ≤40% referred to two outpatient cardiology departments (Sahlgrenska University 
Hospital/Sahlgrenska and Sahlgrenska University Hospital/Östra) between January 
2000 and January 2008.
Methods
One inclusion criterion was the titration of ACEI/ARB and/or BB to either maximal 
tolerated dose or target dose for guideline-recommended HF medications. This was 
performed by our HF specialist nurses over 3–6 months. Titration ended after reach-
ing target dose or the highest tolerated dose. Target doses for ACEIs, ARBs, and BBs 
were based on the European Society of Cardiology guideline recommendations.118
The study cohort was divided into three groups according to ACEI/ARB and/or BB 
doses: low, intermediate, and target dose (<50% of target dose, ≥50% to <target dose, 
and target dose, respectively), Figure 1. The primary outcome was 5-year all-cause 
mortality and secondary outcomes were 5-year cardiac mortality and hospitalization 
due to worsening HF.
Figure 1. Defi nition of target dose strata.
Statistical analysis
Cox proportional hazards regression analysis was used to analyze possible associa-
tions between the three different doses of each agent (ACEI/ARB and/or BB) and 
survival. Kaplan-Meier analysis and univariate Cox proportional-hazard regression 
analysis were used to build multivariate models.
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Paper II
Study population
All patients registered in SwedeHF between May 2000 and December 2012 consti-
tuted the study population. Exclusion criteria were: 1) death during hospitalization; 2) 
incomplete information about EF; and 3) existence of valvular disease with clinical 
signifi cance as reported in the SwedeHF, Figure 2.
Figure 2. Patient fl ow chart.
Methods
Data were collected from the SwedeHF, which was linked with the National Patient 
Register and the Cause of Death Register. The study cohort was divided into two 
groups, HFrEF and HFpEF. HFrEF was defi ned as EF <50% and HFpEF as EF ≥50% 
according to the defi nitions in the 2012 European Society of Cardiology guidelines.118 
The ten non-cardiac comorbidities included in the investigation were: hypertension, 
diabetes, stroke/transient ischemic attack (TIA), anemia, renal failure, pulmonary dis-
ease, liver disease, sleep apnea, gout, and cancer within the previous 3 years. The 
primary outcome was all-cause mortality until December 31, 2012.
Statistical analysis
Multivariate Cox regression analyses were performed for the different variables at the 
index date, calculating hazard ratios (HRs) with 95% confi dence intervals (CIs) for 
mortality. To examine trends over time for the contribution to mortality by each co-
morbidity, similar model analyses were performed separately for HFrEF and HFpEF, 
but also including fi ve consecutive periods (2000–2004, 2005–2006, 2007–2008, 
2009–2010, and 2011–2012) and the interaction between comorbidity and periods.
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Paper III
Study population
A randomly selected sample of half of all men born in 1943 and living in the city of 
Gothenburg, Sweden, were invited in 1993 to participate in the study named “Men 
Born In 1943”, a longitudinal, prospective cohort study investigating cardiovascular 
risk factors and diseases. Of the 1463 men invited, 798 (55%) accepted participation 
and underwent a health examination at entry. Men who were alive and still resident 
in Sweden were invited to a second examination in 2003 and a third examination in 
2014.
Methods
The three examinations included a physical examination, blood testing, and question-
naires concerning medical history, lifestyle, physical activity, and mental wellbeing. 
In addition, echocardiographic assessment was included in the 2014 examination. A 
panel of biomarkers, (NT-proBNP, hs-CRP, IL-6, and cystatin C) were analyzed. HF 
during follow-up was identifi ed through a combination of three procedures: 1) a data 
fi le with the personal identifi cation number of the men run against the National Patient 
Register and the Swedish National Cause of Death Registry; 2) a review of medical 
records from additional cases identifi ed at the examinations; and 3) results from the 
echocardiographic examination in 2014.
Statistical analysis
Multivariate logistic regression models were used to examine the association of each 
biomarker with the incidence of HF adjusted for body mass index (BMI) and hyper-
tension. Odds ratios (ORs) with 95% CIs were presented along with the area under the 
receiver operating characteristic (ROC) curve as a measure of predictive performance. 
For NT-proBNP, IL-6, and cystatin C, median levels were applied as cut-off levels. 
For hs-CRP, cut-off levels were set to 1 and 3mg/L in accordance with previous stud-
ies.
Paper IV
Study population
Two population samples of men born in 1913 and 1943 were fi rst examined at age 
50 years in 1963 and 1993, respectively, and followed longitudinally over 21 years. 
For the sample of men born in 1913, repeated examinations were conducted in 1967, 
1973, and 1980. For the sample of men born in 1943, the methodology has been de-
scribed in Paper III.
Methods
The same study protocol was used for both cohorts and included physical examina-
tion and questionnaires concerning medical history, lifestyle, physical activity, and 
mental wellbeing as well as blood samples at baseline. The defi nition of HF used in 
both cohorts was: 1) hospitalization with a diagnosis of HF either as a principal or a 
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secondary diagnosis; or 2) death with an underlying cause of HF reported in the Swed-
ish National Cause of Death Registry.
Statistical analysis
Cox proportional hazards regression analysis was used to examine the impact of dif-
ferent factors on the risk of developing HF and to compare the impact of these fac-
tors between the two cohorts. Analysis was performed using both characteristics at 
baseline (at 50 years of age) and time-dependent variables (atrial fi brillation, diabetes 
mellitus, and ischemic heart disease). HR per unit increase in standard deviation (SD) 
was used to rank the importance of risk factors in each cohort. Multivariate models 
were then built in a stepwise procedure using the results from the univariate analyses.
Methodology summary for Papers I–IV
An overview of the methodology for Papers I–IV is given in Table 5.
 Paper I Paper II Paper III Paper IV 
Study design Retrospective Retrospective Longitudinal Longitudinal 
Study 
population 
HF patients 
EF ?40%, age ?80 
years 
HF patients 
SwedeHF 
Randomly selected 
population sample 
Two randomly selected 
population samples 
born 30 years apart 
Comparison HF medication 
High vs low doses 
HF phenotypes 
HFrEF vs HFpEF 
Biomarkers 
High vs low levels 
Risk factors 
Presence vs absence 
Outcomes All-cause mortality 
Cardiac mortality 
HF hospitalization 
All-cause mortality Incident HF Incident HF 
Statistical 
analysis 
Cox regression 
analysis 
Cox regression 
analysis 
Logistic regression 
analysis 
Cox regression  
analysis 
EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved EF; HFrEF, heart failure with reduced 
ejection fraction; SwedeHF, Swedish Heart Failure Registry. 
Table 5. Methodology overview
Ethics
All the study protocols in this thesis were approved by the Ethical Committee at the 
University of Gothenburg and conformed to the principles outlined in the 1964 Dec-
laration of Helsinki and its subsequent amendments except for the fi rst examination of 
the cohort of men born in 1913 in 1963 where only oral informed consent was given.
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RESULTS
Paper I
A total of 184 patients fulfi lled the inclusion criteria and constituted the study cohort. 
The mean age of the patients was 83 years. After titration, only 14% of patients were 
treated with the target doses of both ACEI/ARB and BB. The target dose of ACEI/
ARB was achieved in 53% of patients and that of BB by 21% (Table 6).
Drugs No. of patients (%) 
 Low dose 
(<50% of target) 
Intermediate dose 
(?50% to <target) 
Target 
(100%) 
ACEI/ARB 47 (26) 39 (21) 98 (53) 
BB 92 (50) 54 (29) 38 (21) 
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-blocker. 
Table 6. Doses after titration
The study results are summarized in Table 7. The 5-year all-cause mortality was 77% 
and 5-year all-cause mortality was 61%. There were no signifi cant differences in non-
cardiac mortality and non-cardiac hospital admissions between the three different 
dose-groups of ACEI/ARB and/or BB.
 HR (95% CI) p-value 
All cause mortality: target vs low 
dose ACEI/ARB 
0.6 (0.4–0.9) 0.03 
Cardiac cause mortality: target vs low 
dose ACEI/ARB 
0.5 (0.2–0.8) 0.005 
All cause mortality: target vs low 
dose BB 
0.7 (0.5–1.2) 0.2 
Cardiac mortality: target vs low dose 
BB
0.7 (0.4–1.4) 0.4 
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BB, beta-
blocker; CI, confidence interval; HR, hazard ratio. 
Table 7. Main study results
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For ACEI/ARBs, the target dose was associated with reduced all-cause and cardiac 
mortality compared to <50% of target dose (HR 0.6, 95% CI 0.4–0.9; p=0.03). No sig-
nifi cant differences were found between target dose and intermediate dose or between 
intermediate dose and lower dose.
For BBs, there were no signifi cant differences in survival between the three groups. 
It is, however, important to mention that there were no signifi cant differences in heart 
rate after titration of BB between the three dose groups.
Paper II
Between May 2000 and December 2012, 31,344 patients (79.3% HFrEF, 20.7% HF-
pEF) in the SwedeHF were retained for analysis after exclusions.
Patients with HFpEF were older (mean age 77 vs 71 years), more likely to be women 
(53% vs 31%), and had a higher prevalence of atrial fi brillation and a lower preva-
lence of ischemic heart disease compared to those with HFrEF. Patients with pre-
served EF had a higher prevalence of all non-cardiac comorbidities except for renal 
failure, which had a similar age-adjusted prevalence in both groups. The prevalence 
of non-cardiac comorbidities is summarized in Table 8.
Variable No. of patients (%) Age-adjusted 
p-value 
Total 
(n = 31,344) 
HFrEF 
(n = 24,856) 
HFpEF 
(n = 6488) 
Hypertension 21,684 (69.2) 16,418 (66.1) 5266 (81.2) <0.0001 
Diabetes 8732 (27.9) 6780 (27.3) 1952 (30.1)  <0.0001 
Stroke/TIA 5041 (16.1) 3778 (15.2) 1263 (19.5) 0.0003 
Anemia 11,231 (35.8) 8399 (33.8) 2832 (43.7)  <0.0001 
Renal failure 14,706 (47.1) 11,155 (45.0) 3551 (54.9) 0.47 
Lung disease 8954 (28.6) 6676 (26.9) 2278 (35.1)  <0.0001 
Liver disease 501 (1.6) 370 (1.5) 131 (2.0) <0.0001 
Sleep apnea 1132 (3.6) 835 (3.4) 297 (4.6)  <0.0001 
Gout 1329 (4.2) 998 (4.0) 331 (5.1) 0.026 
Cancer within 
previous 3 years 
4108 (13.1) 3094 (12.4) 1014 (15.6)  0.0042 
HFpEF, heart failure with preserved EF; HFrEF, heart failure with reduced ejection fraction; TIA, transient ischemic 
attack. 
Table 8. Prevalence of non-cardiac comorbidities
All-cause mortality until December 31, 2012 was 34.3% in the HFrEF group and 
40.3% in HFpEF group. The age-adjusted mortality rate was 11.1 (CI 95% 10.9–11.4) 
and 10.6 (CI 95% CI 10.1–11.0) per 100 person-years, respectively. The association 
between comorbidities and mortality is summarized in Table 9.
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Stroke, anemia, gout, and cancer had a similar impact on mortality in both phenotypes, 
whereas diabetes, kidney failure, and liver disease had a higher impact on mortality in 
HFrEF patients. Pulmonary disease was more prominent in those with HFpEF. Sleep 
apnea was not associated with a worsened prognosis in either group.
An increased number of comorbidities was associated with higher risk of mortality 
in both HF phenotypes according to multivariate survival analysis without signifi cant 
differences for the impact on mortality between the two HF phenotypes. The adjusted 
HR for patients with one comorbidity vs no comorbidities was 1.37 (95% CI 1.20–
1.57) for HFrEF and 1.60 (95% CI 1.07–2.38) for HFpEF. Adjusted HR for patients 
with seven comorbidities was 7.63 (95% CI 5.55–10.50) for HFrEF and 6.59 (95% CI 
3.89–11.16) for HFpEF.
During follow-up (2000–2012), no statistically signifi cant interaction was found be-
tween periods and the effect of each comorbidity on mortality.
Paper III
In total, 85 of 747 (11.4%) of the participants developed HF during the 21-year fol-
low-up. Thirteen of the 85 patients (15.2%) died by the end of the study. More than 
half of the HF cases (55%) were diagnosed at the last examination in 2014 when an 
echocardiographic examination was performed. The majority (37 of 47, 78.7%) of the 
new cases had HFpEF.
According to logistic regression analysis, biomarkers associated with higher OR for 
developing HF were NT-proBNP and hs-CRP. No association was observed for IL-6 
or cystatin-C and HF (Table 10).
Variable  HFrEF  HFpEF p-value for 
interaction 
with EF HR (95% CI) p-value  HR (95% CI) p-value 
Hypertension 0.96 (0.91–1.00) 0.051 0.85 (0.77–0.93) 0.0007 0.0063 
Diabetes 1.57 (1.50–1.65) <0.0001  1.39 (1.27–1.51) <0.0001 0.0002 
Stroke/TIA 1.36 (1.29–1.43) <0.0001 1.30 (1.19–1.43) <0.0001 0.10 
Anemia 1.70 (1.63–1.78) <0.0001  1.65 (1.53–1.79) <0.0001 0.42 
Renal failure 1.65 (1.57–1.73) <0.0001 1.44 (1.32–1.57) <0.0001 0.0031 
Lung disease 1.46 (1.40–1.53) <0.0001  1.66 (1.54–1.80) <0.0001 0.0066 
Liver disease 2.13 (1.83–2.47) <0.0001 1.42 (1.09–1.85) 0.0084 0.015 
Sleep apnea 1.11 (0.96–1.27) 0.15  1.17 (0.94–1.45) 0.16 0.83 
Gout 1.57 (1.43–1.72) <0.0001 1.38 (1.17–1.62) 0.0001 0.051 
Cancer within 
previous 3 years 
1.35 (1.28–1.43) <0.0001  1.35 (1.22–1.49) <0.0001 0.84 
CI, confidence interval: EF, ejection fraction; HFpEF, heart failure with preserved EF; HFrEF, heart failure with reduced 
ejection fraction; HR, hazard ratio; TIA, transient ischemic attack. 
Table 9. Association between comorbidities and mortality
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For the combination of NT-proBNP ≥25ng/L and hs-CRP >3mg/L, the estimated OR 
was 2.82 (95% CI 1.53–5.18). A model including BMI, hypertension, NT-proBNP, 
and hs-CRP was built with stepwise logistic regression analysis. The probability 
of developing HF in individuals with NT-proBNP ≥25ng/L, hs-CRP >3mg/L, BMI 
≥25kg/m2, and hypertension was 0.33 (95% CI 0.23–0.45). On the contrary, the prob-
ability was only 0.04 (95% CI 0.02–0.07) for those with normal BMI, normal blood 
pressure, NT-proBNP <25ng/L, and hs-CRP ≤3mg/L.
Paper IV
The incidence of HF in men born in 1943 living in Gothenburg was 5.3% (42 of 793), 
whereas that for men born in 1913 was 9.4 % (80 of 855). The event rates were 2.67% 
(95% CI 1.97–3.62) and 4.95 (95% CI 3.98–6.16) per 1000 person-years for the 1943 
and 1913 cohorts, respectively. 
After adjusting for baseline characteristics, men born in 1943 had a 54% lower risk of 
developing HF compared to men born 30 years earlier (HR 0.46, 95% CI 0.28–0.74, 
p=0.002).
Characteristics associated with higher HF risk in both cohorts were higher BMI, 
higher diastolic blood pressure, treatment for hypertension, onset of atrial fi brillation, 
ischemic heart disease, and diabetes mellitus. Higher heart rate was associated with 
an increased risk only in men born in 1913, whereas higher systolic blood pressure 
(SBP), smoking, higher glucose levels, higher total cholesterol levels, and physical 
inactivity were associated with a higher risk of HF for men born in 1943 (Table 11).
Variable Value OR (95% CI) p-value 
NT-proBNP, ng/L ?25 2.09 (1.30–3.36) 0.0024 
hs-CRP, mg/mL >1 1.72 (1.02–2.90) 0.040 
hs-CRP, mg/mL >3 2.61 (1.59–4.29) 0.0002 
IL-6, ng/L >1.88 1.50 (0.94–2.39) 0.089 
Cystatin C, mg/L >0.89 1.15 (0.73–1.83) 0.54 
CI, confidence interval; hs-CRP, high-sensitivity C-reactive protein; IL-6, interleukin-6; NT-proBNP, N-
terminal prohormone of B-type natriuretic peptide; OR, odds ratio. 
Table 10. Association between biomarkers and heart failure
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Men born in 1913  Men born in 1943 
Risk factor HR (95% CI)  Risk factor HR (95% CI) 
BMI 1.11 (1.04–1.19)  BMI 1.19 (1.11–1.28) 
DBP 1.09 (1.00–1.18)  DBP 1.18 (1.03–1.35) 
BP medication use 4.31 (1.58–11.79)  BP medication use 4.20 (1.94–9.09) 
Atrial fibrillation 29.17 (17.40–48.90)  Atrial fibrillation  13.98 (7.43–26.32) 
Ischemic heart disease 7.95 (4.81–13.12)  Ischemic heart disease 6.23 (3.28–11.83) 
Diabetes mellitus 2.18 (1.04–4.53)  Diabetes mellitus 3.28 (1.60–6.71) 
Heart rate ?66/min 0.85 (0.67–1.06)  SBP ?130 mmHg 0.91 (0.61–1.35) 
Heart rate >66/min 1.20 (1.08–1.34)  SBP >130 mmHg 1.45 (1.18–1.78) 
   Smoking 2.84 (1.18–6.85) 
   Glucose level 1.33 (1.22–1.46) 
   Cholesterol level 1.34 (1.01–1.78) 
   Physical inactivity 2.31 (1.18–4.51) 
BMI, body mass index; BP, blood pressure; CI, confidence interval; DBP, diastolic blood pressure; HR, hazard ratio; SBP, 
systolic blood pressure. 
Risk factor HR (95% CI) Interaction p-value 
 Men born in 1913 Men born in 1943  
Atrial fibrillation 29.17 (17.40–48.90) 13.98 (7.43–26.32) 0.031 
SBP ?130 mmHg 1.09 (0.75–1.59) 0.91 (0.61–1.35) 0.52 
SBP >130 mmHg 1.10 (0.97–1.24) 1.45 (1.18–1.78) 0.021 
Physical inactivity 1.02 (0.64–1.64) 2.31 (1.18–4.51) 0.048 
CI, confidence interval; HR, hazard ratio; SBP, systolic blood pressure. 
Table 11. Risk factors for heart failure
Table 12. Secular trends in risk factors for heart failure
The comparison of the impact of different characteristics on HF between the two 
cohorts showed that the importance of atrial fi brillation as a risk factor for HF has 
decreased and that of SBP and physical inactivity has increased in men born in 1943 
compared to those born thirty years earlier (Table 12).
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DISCUSSION
Neurohormonal blockade: does the dose matter in elderly patients with 
HFrEF?
The results from Paper I suggest that the target dose of ACEIs or ARBs is associated 
with lower all-cause and cardiac mortality in elderly patients with HF and EF <40%. 
However, the target dose was achievable in only half of the patients. On the other 
hand, the target dose of BB was not associated with benefi ts in terms of either all-
cause or cardiac mortality.
In clinical practice, an HF patient is commonly older than participants in randomized 
clinical trials. The average age seen in most landmark HF trials is somewhere between 
60 and 70 years.24, 25, 27, 29, 33 Hence, the evidence for treating elderly patients is mostly 
extrapolated from cohorts that are two decades younger. In fact, some trials excluded 
patients >80 years of age.25, 26 In addition, the treatment of HF in the elderly can be 
challenged by the presence of multiple comorbidities, polypharmacy, lower tolerabil-
ity, and a lack of social support.119
Our study cohort should be regarded as representative of real-world clinical settings. 
All patients were subjected to optimal dose titration, implying that dose levels should 
be the highest tolerable as all patients were referred to specialist HF outpatient clinics 
where titration of HF medication was conducted by HF specialist nurses in coopera-
tion with a cardiologist over a maximum period of 6 months.
After titration, 53% of the participants were treated with the target dose of ACEI/ARB 
and only 21% with the target dose of BB. The target dose for both agents was only 
achievable for 14% of patients. The dose levels in our study are comparable to those 
of previous studies despite our cohort being older and with more comorbidities. In the 
Improve-HF Study, the target dose of ACEI/ARB and BB were achieved in 38% and 
30% of participants, respectively.45
Achieving the target dose of ACEI/ARB was associated with reduced mortality com-
pared to a low dose. This fi nding is accordance with previous studies47, 48, 50 and im-
plies the value of titrating of this medication to improve prognosis, even in elderly 
patients. With respect to BBs, no statistically signifi cant differences in survival were 
observed between the three dose groups. A possible explanation is that the mean heart 
rate after titration was similar across groups. Therefore, achieving an optimal heart 
rate may be more important for outcome than the dose itself, which is in line with 
previous studies.120, 121
The importance of non-cardiac comorbidities for mortality in HF: are 
there any differences between HFrEF and HFpEF?
By access to SwedeHF, our data confi rms the high burden of non-cardiac comorbidi-
ties in both HFrEF and HFpEF patients. With the exception of renal failure where the 
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age-adjusted prevalence was similar between groups, non-cardiac comorbidities were 
more common in patients with HF and preserved EF. Our fi ndings are in line with 
previous publications with more women, higher mean age, higher prevalence of atrial 
fi brillation, and lower prevalence of ischemic heart disease in HFpEF compared to 
HFrEF patients.57, 58 After adjustment for age, patients with HFpEF had a slightly 
lower mortality rate.
Our study not only confi rms previous observations that non-cardiac illnesses confer 
signifi cant risk for mortality in HF patients53 but also extends present knowledge by 
demonstrating some notable differences on the impact between the two HF pheno-
types in contrast to some previous studies.67, 69, 122
The relative contribution to mortality was similar comparing HFrEF and HFpEF for 
stroke/TIA, anemia, gout, and cancer. Diabetes mellitus, renal failure, and liver dis-
ease were more prominent in patients with HFrEF, while pulmonary disease was more 
prominent in patients with HFpEF. Hypertension seems to be a protective factor for 
mortality in both HF groups, with a slightly higher impact in HFpEF patients. A pos-
sible explanation for the protective nature of hypertension is that it refl ects the benefi -
cial effect of antihypertensive treatment on mortality. Sleep apnea was not associated 
with a higher risk for mortality in either group. The low prevalence of sleep apnea 
reported in the registry (3.6%), which is much lower than previously reported,51, 123 
raises the suspicion of either under-diagnosis or low reporting rates in the registry.
No signifi cant variations in the trend was observed with respect to the impact of co-
morbidities on mortality between 2000 and 2012 despite treatment for some of these 
comorbidities having improved over this period of time.93, 124, 125 One reason might be 
that the period that was investigated was too short to show changes in the impact of 
comorbidities on mortality in HF patients. Another reason is, perhaps, that the im-
proved therapy of non-cardiac comorbidities is not suffi cient to improve HF outcome 
or that the management of these comorbidities remains suboptimal in many HF pa-
tients. In addition, it is possible that many of the non-cardiac comorbidities remain 
under-diagnosed and under-treated: therefore, they negatively affect prognosis con-
tinuously or many of the non-cardiac comorbidities are diagnosed too late to modify 
prognosis.
Biomarkers as predictors of HF: is it possible to make risk stratifi cation 
of incident HF over 20 years?
The results from Paper III suggest that both NT-proBNP and hs-CRP can act as predic-
tors for the development of HF over 20 years in middle-aged men from the general 
population. A combination of both biomarkers in combination with clinical variables 
such as hypertension and BMI >25 kg/m2 can enhance the predictive value. To our 
knowledge, our study had the longest follow-up (21 years) compared to previous stud-
ies. Our results confi rm those from a previous study in 2010 of a Swedish cohort 
where both biomarkers predicted the incidence of HF.68 However, the association in 
our cohort was found with the same biomarkers but at much lower levels.
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On the basis of our fi ndings, we may speculate that the mechanisms by which brain 
natriuretic peptide is secreted (such as wall stretching and neurohormonal activation) 
are probably present at a very early stage and, together with other mechanisms (such 
as infl ammation), constitute the initial pathophysiology underlying HF. The predictive 
value of NT-proBNP and hs-CRP was present even in those at 50 years of age and 
with a history of cardiovascular events, such as myocardial infarction and atrial fi bril-
lation, according to the sensitivity analysis. 
Incidence and risk factors of HF: have they changed the past 30 years?
Paper IV demonstrates that men born in 1943 had half the risk of HF development 
after 50 years of age compared to those born 30 years earlier. In addition, the risk 
profi le of HF has also changed. Atrial fi brillation, obesity, ischemic heart disease, 
diabetes, and hypertension remain important risk factors. The relative importance of 
atrial fi brillation as a risk factor for HF decreased considerably in men born in 1943, 
whereas SBP and physical inactivity during leisure time proved to be more important 
as risk factors for HF in this cohort.
The reported decreased incidence of HF in our study is consistent with other studies, 
suggesting a decrease in the incidence of HF since the mid-1990s.14-16 This fi nding 
might be explained by continuous improvements in both modifi cations of risk fac-
tors and therapy of several cardiovascular diseases. The later cohort in our study had 
lower mean systolic and diastolic blood pressure, lower percentage of smokers, and 
lower cholesterol levels compared to the older cohort. Our hypothesis about improved 
management of cardiovascular diseases as a possible explanation for the decreased 
HF incidence is supported by the fact that 83% of participants with atrial fi brillation 
in the older cohort developed subsequent HF, whereas only 20% of those with atrial 
fi brillation in the later cohort had new-onset HF. Likewise, for ischemic heart disease, 
the proportion of men with new-onset HF has decreased from 20% in the older cohort 
to 13% in the later cohort. 
The comparison of the impact of each risk factor on the incidence of HF between the 
two cohorts showed that the relative importance of atrial fi brillation as a risk factor 
has decreased, probably because of its improved management in recent years includ-
ing better rhythm and rate control as well as the use of ablation as a treatment option. 
The relative importance of SBP and of physical inactivity has increased in men born 
1943 compared to those born 30 years earlier. SBP was found to be associated with 
higher risk only in the later cohort and at levels above 130 mmHg, suggesting that a 
target of SBP of below 130 mmHg when treating hypertension could be benefi cial 
for the prevention of HF. The association of a high physical activity level with a low 
incidence of HF has been demonstrated previously.87 In our study, data about physical 
activity was only available for leisure time and not for work-related physical activity. 
A possible explanation for why physical inactivity during leisure time seems to be of 
greater importance for the development of HF in men born in 1943 is that these men 
were probably generally less physically active during working hours than those born 
30 years earlier.
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Strengths and limitations
One of the strengths in Paper I is the real-life cohort of elderly patients with HF, which 
allows us to study the impact of the dose effect of HF medication on mortality after 
optimal dose titration. However, the fact that all patients included come from special-
ist clinics is a limitation for the generalizability of the results to patients who do not 
have follow-up at specialist HF outpatient clinics. Another strength is that the data 
was validated by review from a medical journal. The low number of patients included 
in the analysis is a limitation as well as the lack of randomization and the retrospective 
nature of the study.
The strengths of Paper II are the large sample size in a real-world cohort and that the 
data were linked to the Swedish national health data registries, which are obligatory 
for all health providers in Sweden and cover a long follow-up period. Like many other 
registry studies, a limitation of our study is the risk of confounding and selection bias. 
Not all care providers register HF patients in the SwedeHF, so we cannot exclude the 
scenario that care providers who do not include patients in the registry are less suc-
cessful with HF care. Both confounding and selection bias affect the extrapolation of 
the results. Furthermore, the limited information about comorbidities and, in particu-
lar, the lack of information about the severity or staging of comorbidities is a restric-
tion for further assessing the contribution of each comorbidity to mortality.
A strength of Paper III is the use of a random population-based approach and, more-
over, the long duration of longitudinal follow-up. The collection of data about HF 
through review of medical records, the use of the National Patient Register, and the 
echocardiographic examination all helped to reduce the risk of misclassifi cation of 
the outcome. Once again, the relative low number of participants is a limitation as it 
is the absence of women. Another limitation is that echocardiographic examinations 
were not performed at baseline. Thus, the possibility cannot be fully excluded that 
some participants already had heart dysfunction when they were initially included in 
the study as 50-year-olds.
A major strength of Paper IV is that two representative population samples of the 
same age and from the same geographic region were investigated using the same 
methodology. The long follow-up duration with a minimal loss of patients during 
follow-up further strengthens the study. As mentioned above, the low number of par-
ticipants and the absence of women are limitations. The fact that the rates of participa-
tion were 88% in men born in 1913 and 55% in men born in 1943 might have affected 
the results.
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CONCLUSIONS
•      Achieving the target dose of ACEI/ARB is associated with lower all-cause and 
cardiac mortality compared to those who received a low dose (<50% of target 
dose) in elderly patients with HF and EF <40%. With respect to BBs, no statisti-
cally signifi cant differences in survival were observed between target dose groups. 
•      Non-cardiac comorbidities had a signifi cant impact on mortality in HF patients 
regardless of EF but with some notable intergroup differences. An increased num-
ber of comorbidities was associated with a higher risk of mortality in both HFrEF 
and HFpEF phenotypes. No change was found in the trend of the prognostic im-
pact of the comorbidities on HF over the study period despite improvements in 
HF therapy and treatment of comorbidities.
•       NT-proBNP ≥25 ng/L and elevated hs-CRP levels in men aged 50 years were 
predictive biomarkers for the incidence of HF over a 21-year follow-up.
•       The incidence of HF has decreased in middle-aged men living in Gothenburg 
during the past three decades and there has been consequential changes in the risk 
profi le for the development HF. However, atrial fi brillation, obesity, ischemic 
heart disease and hypertension remain important risk factors. 
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CLINICAL IMPLICATIONS
This thesis covers a signifi cant challenge in the management of HF, namely the prog-
nosis of HF as well as the prediction of HF in the general population.
The patients included in Paper I are very commonly encountered in daily clinical 
practice and how to treat them optimally remains a challenge, even for specialist HF 
physicians. It is not unusual that these patients receive lower than target doses of HF 
medications or even no dosing at all. Our results suggest that titration to the target 
dose of ACEI/ARBs appears benefi cial with respect to outcome and should not, there-
fore, be neglected by physicians. With respect to BB treatment, it appears that heart 
rate is more important than the fi nal dose. BBs are probably the most effective agents 
for heart rate control. Therefore, it is reasonable to regulate heart rate in HF, prefer-
ably by use of appropriate BB doses until an optimal heart rate is achieved.
Our fi ndings in Paper II add important information about the signifi cant contribu-
tion of non-cardiac comorbidities to mortality in both HFrEF and HFpEF. This is an 
important message as there is a misperception that comorbidities are more of a driv-
ing factor for worsening prognosis in patients with HFpEF compared to those with 
HFrEF. On the basis of our fi ndings, a greater focus on the early recognition and treat-
ment of comorbidities in both HF phenotypes is justifi ed.
Paper III demonstrated the predictive value of low levels of NT-proBNP and hsCRP 
for the incidence of HF in middle-aged men. The clinical relevance is that the use of 
biomarkers in combination with certain clinical characteristics such as hypertension 
and BMI as risk factors may improve the identifi cation of individuals from the gen-
eral population at a higher risk of HF development, thus enabling early preventive 
measures.
The results from Paper IV suggest that the improved management of risk factors and 
of cardiovascular diseases, such as atrial fi brillation, has led to a decreased incidence 
of HF. However, the incidence of HF remains high, risk factors are not optimally 
managed, and new risk factors are emerging. Therefore, we are still facing serious 
challenges about how to further modify risk factors such as atrial fi brillation, ischemic 
heart disease, diabetes mellitus, and hypertension as well as how to manage new risk 
factors in order to prevent the development of HF in the future.
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